Daily Cardiology Research Analysis
Three high-impact cardiovascular studies stood out today: antisense inhibition of APOC3 with olezarsen markedly lowered triglycerides and reduced acute pancreatitis in severe hypertriglyceridemia; evolocumab (a PCSK9 inhibitor) reduced first cardiovascular events in patients without prior MI or stroke; and an individual-patient meta-analysis showed no benefit of beta-blockers after MI when LVEF is preserved. Together, these findings refine lipid-targeted prevention and support de-implementation
Summary
Three high-impact cardiovascular studies stood out today: antisense inhibition of APOC3 with olezarsen markedly lowered triglycerides and reduced acute pancreatitis in severe hypertriglyceridemia; evolocumab (a PCSK9 inhibitor) reduced first cardiovascular events in patients without prior MI or stroke; and an individual-patient meta-analysis showed no benefit of beta-blockers after MI when LVEF is preserved. Together, these findings refine lipid-targeted prevention and support de-implementation of legacy therapies.
Research Themes
- Precision lipid therapeutics and event prevention
- Primary prevention expansion with PCSK9 inhibition
- De-implementation of legacy therapies post-MI with preserved EF
Selected Articles
1. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.
In two parallel, double-blind RCTs totaling 1,061 patients with severe hypertriglyceridemia, monthly olezarsen reduced triglycerides by roughly 50–72 percentage points vs placebo at 6 months and significantly lowered acute pancreatitis incidence (rate ratio 0.15). Safety was acceptable overall, though higher-dose (80 mg) was associated with more liver enzyme elevations, thrombocytopenia, and increased hepatic fat fraction.
Impact: This is the first program to demonstrate that APOC3 antisense therapy not only lowers triglycerides profoundly but also reduces acute pancreatitis in high-risk patients, establishing event-level benefit beyond lipid changes.
Clinical Implications: Olezarsen offers a disease-modifying option for severe hypertriglyceridemia to prevent pancreatitis. Clinicians should consider dose selection and monitor liver enzymes, platelet counts, and hepatic fat, particularly at 80 mg.
Key Findings
- At 6 months, placebo-adjusted triglyceride reduction ranged from −49.2 to −72.2 percentage points across trials and doses (P<0.001).
- APOC3, remnant cholesterol, and non-HDL cholesterol decreased significantly vs placebo at 6 and 12 months.
- Acute pancreatitis incidence was significantly lower with olezarsen (mean rate ratio 0.15; 95% CI 0.05–0.40).
- Higher-dose (80 mg) showed more elevations in liver enzymes, thrombocytopenia, and a dose-dependent increase in hepatic fat fraction.
Methodological Strengths
- Two parallel, double-blind, randomized, placebo-controlled trials with harmonized endpoints
- Robust event assessment across trials and consistent lipid effects at multiple time points
Limitations
- Safety signals at higher dose (liver enzymes, thrombocytopenia, hepatic fat) may constrain dosing
- Follow-up duration limited to 12 months; long-term outcomes and generalizability beyond severe hypertriglyceridemia remain to be defined
Future Directions: Define optimal dosing balancing efficacy and safety, assess long-term pancreatitis and cardiovascular outcomes, and evaluate combination strategies with dietary and other lipid-lowering therapies.
BACKGROUND: Patients with severe hypertriglyceridemia have an increased risk of acute pancreatitis. The efficacy and safety of olezarsen, an antisense oligonucleotide targeting apolipoprotein C-III messenger RNA, have not been established in this population. METHODS: We conducted two double-blind, randomized, placebo-controlled trials (CORE-TIMI 72a and CORE2-TIMI 72b). Patients with severe hypertriglyceridemia were assigned in a 1:1:1 ratio to receive olezarsen at a dose of 50 mg, olezarsen at a dose of 80 mg, or placebo monthly for 12 months. The primary outcome was the percent change from baseline in the triglyceride level at 6 months, reported as the difference between each olezarsen dose group and the placebo group (placebo-adjusted change). Secondary lipid outcomes included the percent change from baseline in the triglyceride level at 12 months and in the levels of apolipoprotein C-III, remnant cholesterol, and non-high-density lipoprotein (non-HDL) cholesterol at 6 months and 12 months. Acute pancreatitis events were assessed across both trials. RESULTS: A total of 1061 patients were included in the primary analysis (617 in the CORE-TIMI 72a trial and 444 in the CORE2-TIMI 72b trial). At 6 months, the placebo-adjusted least-squares mean change from baseline in the triglyceride level was -62.9 percentage points in the olezarsen 50-mg group and -72.2 percentage points in the olezarsen 80-mg group in the CORE-TIMI 72a trial and was -49.2 percentage points in the olezarsen 50-mg group and -54.5 percentage points in the olezarsen 80-mg group in the CORE2-TIMI 72b trial (P<0.001 for all comparisons of olezarsen with placebo). Decreases in the levels of triglycerides, apolipoprotein C-III, remnant cholesterol, and non-HDL cholesterol were greater with olezarsen than with placebo (P<0.001 for all comparisons). The incidence of acute pancreatitis was lower with olezarsen than with placebo (mean rate ratio, 0.15; 95% confidence interval, 0.05 to 0.40; P<0.001). The incidence of any adverse events appeared to be similar across trial groups. Elevations in liver-enzyme levels and thrombocytopenia (platelet count, <100,000 per microliter) were more common with the 80-mg dose of olezarsen, and a dose-dependent increase in the hepatic fat fraction was noted. CONCLUSIONS: Among patients with severe hypertriglyceridemia, treatment with olezarsen led to a significantly greater reduction in the triglyceride level at 6 months and in the incidence of acute pancreatitis than placebo. (Funded by Ionis Pharmaceuticals; CORE-TIMI 72a and CORE2-TIMI 72b ClinicalTrials.gov numbers, NCT05079919 and NCT05552326.).
2. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
In 12,257 patients with atherosclerosis or diabetes and no prior MI or stroke, evolocumab reduced first cardiovascular events over 4.6 years (HR 0.75 for 3-point MACE; HR 0.81 for 4-point MACE) with no safety signal. These data extend event reduction with PCSK9 inhibition into a broader primary prevention population meeting LDL-C ≥90 mg/dL.
Impact: A large, rigorous outcome trial showing PCSK9 inhibitors reduce first events in patients without prior MI/stroke may shift primary prevention strategies in high-risk populations inadequately controlled on standard therapy.
Clinical Implications: Consider evolocumab for high-risk patients (atherosclerosis or diabetes) with LDL-C ≥90 mg/dL who remain above targets despite guideline-directed therapy; shared decision-making should weigh absolute risk, cost, and access.
Key Findings
- Evolocumab reduced 3-point MACE (HR 0.75; 95% CI 0.65–0.86; P<0.001).
- Evolocumab reduced 4-point MACE including ischemia-driven revascularization (HR 0.81; 95% CI 0.73–0.89; P<0.001).
- Safety profiles were similar to placebo over a median of 4.6 years.
Methodological Strengths
- International, double-blind, randomized, placebo-controlled design with long follow-up
- Clinically meaningful, adjudicated composite endpoints with consistent effects
Limitations
- Absolute risk reduction may be modest in some subgroups; cost-effectiveness varies by healthcare system
- Generalizability limited to patients meeting LDL-C ≥90 mg/dL and enrolled risk profiles
Future Directions: Evaluate cost-effectiveness and implementation strategies in primary prevention, define optimal patient selection and combination with ezetimibe/high-intensity statins, and assess longer-term safety.
BACKGROUND: The proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, stroke, or symptomatic peripheral artery disease. The effect of evolocumab on the risk of MACE among patients without a previous myocardial infarction or stroke is unknown. METHODS: We conducted an international, double-blind, randomized, placebo-controlled trial of evolocumab in patients with atherosclerosis or diabetes and without a previous myocardial infarction or stroke who had a low-density lipoprotein cholesterol level of at least 90 mg per deciliter. Patients were randomly assigned in a 1:1 ratio to receive evolocumab at a dose of 140 mg every 2 weeks or placebo. The two primary end points were a composite of death from coronary heart disease, myocardial infarction, or ischemic stroke (3-point MACE) and a composite of 3-point MACE or ischemia-driven arterial revascularization (4-point MACE). RESULTS: A total of 12,257 patients were randomly assigned to receive evolocumab (6129 patients) or placebo (6128) and were included in the efficacy analyses. The median age of the patients was 66 years, 43% were women, and 93% were White. The median follow-up was 4.6 years. A 3-point MACE event occurred in 336 patients (5-year Kaplan-Meier estimate, 6.2%) in the evolocumab group, as compared with 443 (8.0%) in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.65 to 0.86; P<0.001). A 4-point MACE event occurred in 747 patients (5-year Kaplan-Meier estimate, 13.4%) in the evolocumab group, as compared with 907 (16.2%) in the placebo group (hazard ratio, 0.81; 95% CI, 0.73 to 0.89; P<0.001). No evidence of a between-group difference was seen in the incidence of safety events. CONCLUSIONS: PCSK9 inhibition with evolocumab led to a lower risk of first cardiovascular events than placebo among patients with atherosclerosis or diabetes and without a previous myocardial infarction or stroke. (Funded by Amgen; VESALIUS-CV ClinicalTrials.gov number, NCT03872401.).
3. Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction.
An individual-patient meta-analysis of 17,801 participants from five randomized trials found no reduction in all-cause death, MI, or heart failure with beta-blockers after MI when LVEF ≥50% and no other indication exists. These data support deprescribing in this subgroup while focusing on other secondary prevention therapies.
Impact: Provides definitive, patient-level evidence questioning routine beta-blocker use after MI with preserved EF, informing guideline updates and optimizing polypharmacy.
Clinical Implications: For post-MI patients with LVEF ≥50% and no other indication (e.g., arrhythmia, angina), beta-blockers may be safely de-implemented; prioritize statins, antiplatelets, ACEi/ARB, SGLT2i as appropriate.
Key Findings
- No significant difference in the primary composite of all-cause death, MI, or heart failure (HR 0.97; 95% CI 0.87–1.07).
- Component endpoints (all-cause death, MI, heart failure) were each non-significant between groups.
- Findings were consistent across five randomized trials with a median follow-up of 3.6 years.
Methodological Strengths
- Individual-patient data meta-analysis across multiple randomized trials enhancing power and subgroup consistency
- Predefined composite outcomes with robust time-to-event modeling
Limitations
- All included trials were open-label, potentially introducing performance bias
- Heterogeneity in beta-blocker type, dose, and duration; limited power for rare safety endpoints
Future Directions: Clarify subgroups (e.g., microvascular angina, autonomic imbalance) that might benefit; evaluate optimal tapering strategies and patient-centered deprescribing frameworks.
BACKGROUND: The benefit of beta-blockers after myocardial infarction in patients with a preserved left ventricular ejection fraction (LVEF) is unclear. METHODS: We conducted a meta-analysis at the individual-patient level using data from five open-label trials that randomly assigned patients with recent myocardial infarction, no other indications for beta-blocker therapy, and an LVEF of at least 50% to receive beta-blocker therapy or no beta-blocker therapy. The primary end point was a composite of death from any cause, myocardial infarction, or heart failure. Event rates were analyzed with a one-stage fixed-effects Cox proportional-hazards model. RESULTS: A total of 17,801 patients were included from the REBOOT (7459 patients), REDUCE-AMI (4967 patients), BETAMI (2441 patients), DANBLOCK (2277 patients), and CAPITAL-RCT (657 patients) trials. Of these 17,801 patients, 8831 (49.6%) were assigned to receive a beta-blocker and 8970 (50.4%) were assigned to receive no beta-blocker. During a median follow-up of 3.6 years (interquartile range, 2.3 to 4.6), a primary-end-point event occurred in 717 patients (8.1%) in the beta-blocker group and 748 patients (8.3%) in the no-beta-blocker group (hazard ratio, 0.97; 95% confidence interval [CI], 0.87 to 1.07; P = 0.54). Death from any cause occurred in 335 patients in the beta-blocker group and 326 patients in the no-beta-blocker group (hazard ratio, 1.04; 95% CI, 0.89 to 1.21); myocardial infarction occurred in 360 and 407 patients, respectively (hazard ratio, 0.89; 95% CI, 0.77 to 1.03); and heart failure occurred in 75 and 87 patients (hazard ratio, 0.87; 95% CI, 0.64 to 1.19). CONCLUSIONS: In this meta-analysis including individual-patient data from five randomized trials, beta-blocker therapy did not reduce the incidence of death from any cause, myocardial infarction, or heart failure in patients with an LVEF of at least 50% after myocardial infarction without other indications for beta-blockers. (Funded by Centro Nacional de Investigaciones Cardiovasculares Carlos III and others; PROSPERO database number, CRD420251119176.).